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Abstract
Background: Gene interactions play a central role in transcriptional networks. Many studies
have performed genome-wide expression analysis to reconstruct regulatory networks to
investigate disease processes. Since biological processes are outcomes of regulatory gene
interactions, this paper develops a system biology approach to infer function-dependent
transcriptional networks modulating phenotypic traits, which serve as a classifier to identify tissue
states. Due to gene interactions taken into account in the analysis, we can achieve higher
classification accuracy than existing methods.
Results: Our system biology approach is carried out by the Bayesian networks framework. The
algorithm consists of two steps: gene filtering by Bayes factor followed by collinearity elimination
via network learning. We validate our approach with two clinical data. In the study of lung cancer
subtypes discrimination, we obtain a 25-gene classifier from 111 training samples, and the test on
422 independent samples achieves 95% classification accuracy. In the study of thoracic aortic
aneurysm (TAA) diagnosis, 61 samples determine a 34-gene classifier, whose diagnosis accuracy on
33 independent samples achieves 82%. The performance comparisons with three other popular
methods, PCA/LDA, PAM, and Weighted Voting, confirm that our approach yields superior
classification accuracy and a more compact signature.
Conclusions: The system biology approach presented in this paper is able to infer function-
dependent transcriptional networks, which in turn can classify biological samples with high
accuracy. The validation of our classifier using clinical data demonstrates the promising value of our
proposed approach for disease diagnosis.
Background
Genome-wide expression analysis has revolutionized
disease diagnostic models through the identification of
molecular signatures [1], which are selected from high
ranked genes determined by statistical measures, such as
fold change [2], t statistic [3], signal-to-noise ratio [4], or
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Open Accesssubnetwork scores [5]. Over the last decade, system
biology researchers also exploited the comprehensive
transcriptional landscape offered by microarrays to
identify the transcriptional networks that unravel reg-
ulatory gene interactions and explain how diseases
progress [6-8]. Although these two analysis approaches
seem antithetic, they can be unified to create transcrip-
tional network classifiers to enhance disease diagnosis
accuracy. We can regard the transcriptional networks
underpinning disease development as perturbed by the
presence of diseases. The phenotype is treated as a binary
perturbation of the overall transcriptional network. To
reconstruct the classifier, our task is just to infer from
expression profiles the function-dependent transcrip-
tional network that modulates phenotypic traits.
Gene interactions play a central role in transcriptional
networks. Abnormal interactions between gene tran-
scripts will give rise to disease incursion [8,9]. To
develop transcriptional network classifiers, we consider
a system biology approach to capture gene interactions
through the measurements of expression collinearity
between genes. Our approach is carried out by the
Bayesian networks framework, which is a powerful
instrument to delineate dependence networks among
variables. Bayesian networks have been extensively
applied to analyze several types of genomic data,
including gene regulation [10], protein-protein interac-
tions [11], single-nucleotide polymorphisms [12] and
pedigrees [13]. A Bayesian network is a directed acyclic
graph in which nodes represent random variables and
arcs define directed dependencies quantified by prob-
ability distributions. This study considers a mixed
Bayesian network, where the tissue type is represented
by a discrete variable and gene expression levels are
modelled by continuous, log normal, distributions.
Figure 1 illustrates a Bayesian network, where a node
represents a gene or a phenotype, and a directed arc
linking a pair of nodes records the conditional prob-
ability of the child (target) node on the parent (source)
node.
Both the graphical structure of a Bayesian network and
the parameters of the conditional probabilities can be
learned from the available database. Nevertheless,
learning a network is computationally intensive because
ideally the dependent relations of all pairs of variables
must be evaluated. We circumvent the demanding
computations by a two-stage learning process. Our
algorithm begins with the use of Bayes factor to select
the genes that are functionally dependent on the
phenotype, since only function-dependent genes have
potential to play a role in tissue discrimination. Then, we
explore the detailed dependencies between the selected
genes to reconstruct a transcriptional network. After the
transcriptional network is learned, it can be exploited for
tissue classification, again formulated in the Bayesian
networks framework. In the learned network, the
phenotype’s Markov blanket is the set of nodes
composed of the phenotype’s parents, its children, and
its children’s parents. Given the genes under the Markov
blanket, the phenotype is independent of the genes not
covered by the Markov blanket. Hence, only the genes
under the Markov blanket contribute to phenotype
classification, and they assemble a signature. With
reference to Figure 1, genes 1, 2, 3 are those under the
phenotype’s Markov blanket, consisting of a signature
for tissue classification.
Results
We validate our approach by two clinical studies:
discrimination of lung cancer subtypes and diagnosis
of thoracic aortic aneurysm.
Discrimination of lung cancer subtypes
Lung adenocarcinoma (AC) and squamous cell carci-
noma (SCC) are the most common subtypes of lung
cancer. They are heterogeneous in many clinical aspects,
such as responses to chemotherapy [14], tendency to
metastases [15,16], and mortality rates [17,18]. Unfortu-
n a t e l y ,t h ec u r r e n tg o l ds t a n d a r di sh i s t o l o g yw h i c hi s
subjective [19] and may fail when tumors are small [20]
or when patients suffer from multiple types of primary
lung carcinomas [21]. Gene expression profiling will
avoid these problems and perform automatic discrimi-
nation of lung cancer subtypes. The classifier is trained
b yaD u k eU n i v e r s i t yd a t a[ 2 2 ] ,w h i c hi sa v a i l a b l eo n
Figure 1
An example Bayesian network. An o d er e p r e s e n t sa
variable, and a directed arc linking a pair of nodes records
the conditional probability of the child (target) node on the
parent (source) node. In this network, genes 1, 2, 3 are
under the phenotype's Markov blanket, so they form a
signature for phenotype classification.
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GSE3141, in a total of 58 ACs and 53 SCCs. The lung
specimens are assayed by Affymetrix HG-U133A. Figure 2
shows the function-dependent transcriptional network
inferred from the data. Of the 22,283 gene probes in the
microarray, seventy seven probes are dependent, directly
or indirectly, on the carcinoma subtypes. Of these 77
genes, 25 are under the phenotype Markov blanket, so
they per se assemble a signature. Enrichment study shows
that there are 23 unique genes in this signature,
summarized in Table 1.
The performance of 10-fold cross validation achieves
98.5% accuracy. We further test the classification
accuracy of the network on seven independent study
populations with Gene Expression Omnibus accession
numbers GSE10072, GSE7670, GSE12667, GSE4824,
GSE2109, GSE4573, and GSE6253, for a total of 422
samples, 232 AC and 190 SCC, from subjects of
Caucasian, Asian and African descent representing
84.6%, 6.9%, and 2.8% of the data, respectively. On
these independent samples, our transcriptional network
classifier achieves an accuracy of 95.2%.
The 25-gene signature identified by the classifier is
unique to discriminate AC and SCC with high accuracy.
Furthermore, most of these genes have been reported
their specificity to lung cancer. ABCC3, CLDN3, DPP4,
MUC3B, MUC5B, NTRK2, SPINK1, TJP3 are specific
markers of lung AC [23-29]. KRT6A, KRT6B, KRT6C,
KRT17, RHCG, SPRR1A,a n dVSNL1 are unique to lung
SCC [30-33]. BICD2, CDA, NMNAT2, SERPINB13,a n d
TOX3 have no specificity to either AC or SCC but to lung
cancer [34-38].
Diagnosis of thoracic aortic aneurysm
Thoracic aortic aneurysm (TAA) is usually asymptomatic
and associated with high mortality. Identification of at-
risk individuals is a challenging task. Gene expression
patterns in peripheral blood cells are expected to assist
t h ed i a g n o s i so fT A A .T h ed a t au s e dt od e r i v et h e
classifier is publicly available on Gene Expression
Omnibus with accession number GSE9106 [39], which
involves 36 cases and 25 controls for training purpose.
Peripheral blood samples were collected at Yale-New
Haven Hospital. Gene expression experiments were
carried out by Applied Biosystems Human Genome
Survey Microarray v2.0, which is equipped with 32,878
probes. The utilization of Bayes factor in our algorithm
first filters out 346 genes that are dependent on the
phenotype. Bayesian network learning results in the
functional dependence network shown in Figure 3. There
are 34 genes under the phenotype’s Markov blanket, and
they form a signature for TAA diagnosis. Table 2
summarizes the annotations of the signature, where the
nameless genes are provided with their probe identifies
only. The genes ABCG4, ARNT2, BCOR, CABP2, CSTF2,
DNTTIP1, FGG, IGF2BP1, MAL2, MMP11, RBM16,
TM4SF1, ZBTB4, ZNF394 are involved in connective
tissue disorders and inflammatory disease, which are
prerequisite to TAA. The 10-fold cross validation of the
classifier yields 97% accuracy. We further examine the
classifier on the independent samples, 24 cases and 9
controls, also included in the Yale data GSE9106. The
accuracy on these independent samples achieves 82%,
demonstrating good performance of our approach.
Comparisons with other methods
We contrast our proposed system biology approach with
other popular algorithms that do not take into account
regulatory gene interactions:
1) Principal Component Analysis with Linear Dis-
criminant Analysis (PCA/LDA): The PCA/LDA
method begins with reducing the number of genes
to a small number of principal genes and then
searches for a discriminative linear function on
expression values to separate tissues.
2) Prediction Analysis for Microarray (PAM) [40]:
PAM utilizes signal to noise ratios to pick up a
signature and uses the ratios to determine the tissue
types of testing samples.
3) Weighted Voting [1]: This method ranks genes by
t h ef o l dc h a n g eo ft h em e a n so ft h ee x p r e s s i o n
values. The classification is determined by how close
to the high rank genes the testing data is.
Figure 2
The functional dependence network for lung cancer
subtypes characterization. There are 77 genes
dependent on the lung cancer subtypes and they are selected
to build up this network, where 25 genes (in green) are
under the phenotype's Markov blanket to assemble a
signature.
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dependencies among genes, so they yield worse
performance than our TNC. Table 3 and Table 4
summarize the comparisons of our approach with
these methods on the lung cancer and TAA studies,
respectively. The results show that our approach is
superior to other algorithms. On the other hand, our
approach leads to more compact signatures because
collinearity elimination is addressed after gene selec-
tion. The differences between our approach and other
schemes are statistically significant (p < 0.005), except
that weighted voting performs close to ours in the lung
cancer study. Although weighted voting reaches high
classification accuracy on the lung cancer data, it
requires a large number of genes in the signature,
giving rise to overfitting problem.
Discussion
The clinical application confirms improved accuracy of
our proposed system biology approach. Literature survey
on the functions of the signature genes also validates the
capability of our approach to extract biologically reason-
able signatures. Furthermore, the large-scale indepen-
dent test on seven cohorts in the lung cancer study shows
robustness of our classifier across platforms and popula-
tions. The two studies also demonstrate the capability of
our method to analyze data assayed by microarrays
manufactured by different makers.
Table 1: The signature of 25 genes for characterizing lung cancer subtypes. Enrichment shows that there are 23 unique genes in the
signature
Gene symbol Gene title Pathway
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 ABC transporters
BICD2 bicaudal D homolog 2 (Drosophila)
CDA cytidine deaminase Pyrimidine metabolism, Drug metabolism
CLDN3 claudin 3 Cell adhesion molecules, Tight junction,
Leukocyte transendothelial migration
DPP4 dipeptidyl-peptidase 4
HGD homogentisate 1,2-dioxygenase (homogentisate oxidase) Tyrosine metabolism, Styrene degradation
ITPKA inositol 1,4,5-trisphosphate 3-kinase A Inositol phosphate metabolism, Calcium signaling
pathway, Phosphatidylinositol signaling system
KRT14 keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner) Cell communication
KRT6A, KRT6B, KRT6C keratin 6A, keratin 6B, keratin 6C, Cell communication
MUC3B mucin 3B, cell surface associated
MUC5B mucin 5B, oligomeric mucus/gel-forming
NMNAT2 nicotinamide nucleotide adenylyltransferase 2 Nicotinate and nicotinamide metabolism
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 MAPK signaling pathway
RHCG Rh family, C glycoprotein
SERPINB13 serpin peptidase inhibitor, clade B (ovalbumin), member 13
SOX2 SRY (sex determining region Y)-box 2
SPINK1 serine peptidase inhibitor, Kazal type 1
SPRR1A small proline-rich protein 1A
TJP3 tight junction protein 3 (zona occludens 3) Tight junction
TOX3 TOX high mobility group box family member 3
VSNL1 visinin-like 1
Figure 3
The functional dependence network for TAA
diagnosis. There are 346 genes selected to reconstruct this
network, because of their distinct expression patterns
between TAA and normal samples. The signature consists of
the 34 genes (in green) under the phenotypeâ€™sM a r k o v
blanket.
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to specify a cutoff of statistical measures to select
high ranked genes, our method is threshold free for
signature selection, because the signature genes are
determined once the transcriptional network is mod-
elled. For phenotype classification, we need to keep the
network merely composing of the signature genes, and
the remaining network can be discarded; this way
can save storage resources in clinical usage. Another
feature of our transcriptional network classifier is its
visualization of molecular dependence network, which
will provide biologists a clue for gene causality investiga-
tion.
A recent work proposes to use prior knowledge of known
pathway information to select gene subnetworks as features
for tissue classification [5]. However, this method will
discard a major portion of the data, because a large
number of genes have not been discovered their functional
pathways. Dissimilar to this method, our approach fully
utilizes the entire data to screen the function-dependent
genes and to reconstruct the network.
Conclusions
This paper uses a system biology approach to develop
transcriptional network classifiers. The classifier can be
thought of as a gene network perturbed by the presence
Table 2: The signature of 34 genes for diagnosing TAA
Gene symbol Gene title Pathway
ABCG4 ATP-binding cassette, sub-family G (WHITE), member 4
ARNT2 aryl-hydrocarbon receptor nuclear translocator 2
BCOR BCL6 co-repressor
C17ORF63 chromosome 17 open reading frame 63
CABP2 calcium binding protein 2
CSTF2 cleavage stimulation factor, 3' pre-RNA, subunit 2, 64kDa
DEFB105A defensin, beta 1
DNTTIP1 deoxynucleotidyltransferase, terminal, interacting protein 1
FAF2 Fas associated factor family member 2
FGG fibrinogen gamma chain Coagulation system
IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1
IWS1 IWS1 homolog (S. cerevisiae)
KRTAP17-1 keratin associated protein 17-1
KRTAP23-1 keratin associated protein 23-1
MAL2 mal, T-cell differentiation protein 2
MMP11 matrix metallopeptidase 11 (stromelysin 3)
RBM16 RNA binding motif protein 16
TM4SF1 transmembrane 4 L six family member 1
ZBTB4 zinc finger and BTB domain containing 4
ZBTB9 zinc finger and BTB domain containing 9
ZNF394 zinc finger protein 394
[224346]
[101505]
[235845]
[699092]
[684137]
[104523]
[109173]
[152832]
[230015]
[140170]
[234336]
[143814]
[150467]
Table 3: Performance comparisons with other methods on the lung cancer data
Classifier Number of signature genes Accuracy in independent samples p-value
Transcriptional Network Classifier (this research) 25 95.2% —
Principal Component Analysis with Linear Discriminant Analysis 13 91.2% 0.0047
Prediction Analysis for Microarray [40] 77 91.0% 0.0014
Weighted Voting [1] 800 93.4% 0.6240
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framework to model the classifier. The algorithm uses
Bayes factor for gene filtering, followed by collinearity
elimination via network learning. The clinical applica-
tions of our approach to lung cancer subtypes classifica-
tion and TAA diagnosis demonstrate high classification
accuracy of the network based classifiers. The biological
validation of the signatures further confirms the ability
of the transcriptional network classifier to extract mean-
ingful signatures.
Methods
Let Y1,Y2,...,YN be Gaussian random variables represent-
ing the expression levels of genes 1,...,N,a n dC be
a multinomial random variable indicating tissue condi-
tions. We use uppercase to denote random variables and
l o w e r c a s et od e n o t et h e i rv a l u e s .O u ra l g o r i t h mf i r s tu s e s
Bayes factor to filter function-dependent genes and then
exploit Bayesian network learning to eliminate collinear-
ity among these selected genes.
G e n ef i l t e r i n gb yB a y e sf a c t o r
The genes functionally dependent on the phenotype are
filtered in the beginning. The filtering can be realized by
Bayes factor, which evaluates for each gene the ratio of its
likelihood of being dependent on the phenotype to its
likelihood of being independent of the phenotype.
When the Bayes factor is greater than one, the gene is
selected because it is more likely to be dependent on
than to be independent of the phenotype.
Collinearity elimination via network learning
Without loss of generality, we assume that the first G out
of N genes were selected by the preceding step. The gene
expression data under consideration now is D ={ y1,y2,...,
YG,c}. When a gene Yi is collinearly expressed with
another gene Yj, the dependence of gene Yi on the
phenotype is mediated by gene Yj. In other words, our
goal is to search which gene modulates gene Yi with the
highest likelihood. When we find out for every gene its
best upstream variable, the network is achieved. In the
framework of Bayesian network, our objective is to
learn from a set of candidate network models
Ω={} MM M K 12 ,, , … the optimal network ˆ M fit best
to the data D. Equivalently, we look for the highest
posterior probability pM D k () . Applying Bayes’ theorem
to pM D k () results in pM D pM pDM kk k () ( ) () ∝ ,w h e r e
pM k () is the prior probability of model Mk and
pDM k () is the marginal likelihood. The computation
of pDM k () is to average out qk from the likelihood
function pDM kk (, ) q ,w h e r eqk is the values of the
random vector Θk parameterizing the distribution of y1,
y2,...,YG,C conditional on Mk . We can exploit the local
Markov properties encoded by the network Mk to
rewrite the joint probability pDM kk (, ) q as
pDM pcp ac py p ay kk k c g g k g
g
G
(, ) ( ( ) , ) ( ( ) , ) =
= ∏
1
where pa(x) denotes the values of the parents Pa(X)o f
random variables X,a n d kx i st h es u b s e to fp a r a m e t e r s
used to describe the dependence of variable X on its
parents.
In this paper, we model a gene Yg to be dependent on
either the phenotype C or another single geneYa,a n dt h e
phenotype C is the root in the network without parents.
We further can assume the J samples in the database are
independent. The likelihood function becomes
pDM pc py p ay kk jk c
j
J
gj gj kg
g
G
j
J
(, ) () (( ) , ) qq q =
⎡
⎣
⎢
⎢
⎤
⎦
⎥
⎥
×
== = ∏∏
11 1 ∏ ∏
⎡
⎣
⎢
⎢
⎤
⎦
⎥
⎥
where the subscripts j indicate the jth sample. The first
term can be estimated by sample frequencies, and the
second term can be derived using linear Gaussian model
[41]. The marginal likelihood function is the solution of
the integral
pDM pDM p d kk k k k () (, ) ( ) =∫ qq q
Due to limited space, we in this paper do not present the
detailed computation, which can be derived from [41].
Finally, the determination of the best Bayesian network
model is ˆ argmax ( ) ( ) Mp M p D M
k kk = .
Sample classification
The phenotype classification ˆ c of a sample is to find the
maximum probability of the tissue class that the sample
belongs to, conditional on the expression values of the
Table 4: Performance comparisons with other methods on the TAA data
Classifier Number of signature genes Accuracy in independent samples p-value
Transcriptional Network Classifier (this research) 34 81.8% —
Principal Component Analysis with Linear Discriminant Analysis 49 71.6% 10
7
Prediction Analysis for Microarray [40] 41 78.4% 0.0091
Weighted Voting [1] 126 51.9% 10
20
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follows:
ˆ argmax ( , , , ) cp c y y y
c
G = 12 …
,
The application of Bayes’ theorem leads to
ˆ argmax
( , , , )()
(,, , )
c
py y y cpc
py y y c
G
G
=
12
12
…
…
= argmax ( , , , ) ( )
c
G py y y cpc 12 …
where the second equality holds because the denomi-
nator p(y1,y2,...,yG) in the first line is not a function of c.
Since only genes directly dependent on the phenotype
variable C matter in the maximization, the tissue
classification becomes
ˆ argmax ( ) ( ) cp c p y c
c
g
gH
=
∈ ∏
where H denotes the set of genes that are the children of
the phenotype C in the network and assemble a
signature. Equivalently, the set H of genes corresponds
to the genes under the phenotype’sM a r k o vb l a n k e t .
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